ArticleEJNMMI radiopharmacy and chemistry2025
Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[
Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe Neuropeptide Y (NPY) system regulates mood, stress, and feeding behavior and plays a central role in neuropsychiatric and metabolic disorders. It exerts its effects primarily through a family of G-protein-coupled NPY receptors (NPYR), comprising the Y1, Y2, Y4, and Y5 subtypes. Among these, the Y2 receptor (NPY2R) has emerged as a promising imaging target through its involvement in mood regulation, anxiety, and feeding behavior. This study evaluated the in vivo performance of the selective NPY2R antagonist PET tracer N-[
resultsIn vitro, N-methyl-(R)-JNJ-31020028 showed nanomolar affinity and selectivity for the murine NPY2R with no observable interaction with mY1, mY4, and mY5. In vivo, brain percent injected dose per cc (%ID/cc), peaked within the first 5 min after injection and declined rapidly. Tariquidar pretreatment increased brain uptake more than threefold at 15 min post administration, particularly in hippocampus, thalamus, and striatum, but differences disappeared at 60 min. Radiometabolite analysis revealed rapid peripheral metabolism, and absence of intact tracer in the brain at 60 min in vehicle-treated mice. In plasma, the parent fraction was unaffected by tariquidar, while it was significantly higher in the brain with P-gp inhibition. Metabolite-corrected brain-to-plasma concentration ratios (K
conclusionsN-[
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.